MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Eli Lilly and Co.

Slēgts

SektorsVeselības aprūpe

860.32 3.58

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

827.27

Max

862

Galvenie mērījumi

By Trading Economics

Ienākumi

7.8B

8.8B

Pārdošana

2.1B

14B

P/E

Sektora vidējais

70.036

57.333

EPS

5.32

Dividenžu ienesīgums

0.71

Peļņas marža

65.172

Darbinieki

47,000

EBITDA

1.2B

6.1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+16.73% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.71%

2.63%

Nākamie ieņēmumi

2025. g. 1. maijs

Nākamais Ex dividenžu datums

2025. g. 14. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-50B

735B

Iepriekšējā atvēršanas cena

856.74

Iepriekšējā slēgšanas cena

860.32

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. apr. 09:26 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

2025. g. 18. apr. 15:57 UTC

Galvenie tirgus virzītāji

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

2025. g. 17. apr. 11:52 UTC

Galvenie tirgus virzītāji

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

2025. g. 9. apr. 18:18 UTC

Galvenie tirgus virzītāji

Pharma Shares Reverse Losses After Tariff Pause

2025. g. 9. apr. 09:39 UTC

Galvenie tirgus virzītāji

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 1. apr. 23:15 UTC

Galvenie tirgus virzītāji

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025. g. 22. apr. 09:31 UTC

Karstas akcijas

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

2025. g. 17. apr. 18:27 UTC

Top Ziņas

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

2025. g. 17. apr. 10:45 UTC

Top Ziņas

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

2025. g. 11. apr. 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Novo Remade Denmark. Then Came the Stock Selloff. -2-

2025. g. 11. apr. 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

2025. g. 11. apr. 09:30 UTC

Top Ziņas

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025. g. 11. apr. 05:00 UTC

Top Ziņas

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

2025. g. 10. apr. 05:00 UTC

Peļņas

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

2025. g. 8. apr. 21:26 UTC

Peļņas

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2025. g. 2. apr. 16:53 UTC

Top Ziņas

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

2025. g. 1. apr. 22:31 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 1. apr. 21:47 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 19. marts 15:54 UTC

Top Ziņas

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025. g. 14. marts 09:30 UTC

Top Ziņas

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 26. febr. 15:14 UTC

Top Ziņas

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

2025. g. 26. febr. 14:30 UTC

Top Ziņas

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

2025. g. 10. febr. 12:00 UTC

Top Ziņas

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025. g. 7. febr. 10:30 UTC

Top Ziņas

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025. g. 6. febr. 16:16 UTC

Top Ziņas
Peļņas

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025. g. 6. febr. 14:56 UTC

Peļņas

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025. g. 6. febr. 14:32 UTC

Tirgus saruna
Peļņas

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

2025. g. 6. febr. 13:18 UTC

Top Ziņas
Peļņas

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

16.73% augšup

Prognoze 12 mēnešiem

Vidējais 1,003.6 USD  16.73%

Augstākais 1,124 USD

Zemākais 888 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

19 ratings

19

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

732.41 / N/AAtbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.